GSK plc (LSE/NYSE: GSK) announced on 19 November 2026 that its novel KIT inhibitor velzatinib has received Orphan Drug Designation (ODD) from Japan's Ministry of Health Labour and Welfare for the treatment of gastrointestinal stromal tumour (GIST). The designation adds to existing US FDA Fast Track designation and ODDs already granted in the United States and European Union, broadening velzatinib's regulatory recognition across three major markets. With Phase III trials under way and second-line enrolment tracking ahead of schedule, investors will be watching closely as data readouts approach in the second half of 2027.
Key Points
- GSK plc (LSE/NYSE: GSK) is a global biopharma company headquartered in London, England
- Velzatinib has received Orphan Drug Designation in Japan for GIST treatment, adding to US FDA Fast Track and US and EU ODDs
- Phase III trials are under way in first- and second-line advanced/metastatic GIST; second-line data expected in the second half of 2027
- Investors should watch for velzatinib data presentations at the CTOS Annual Meeting 2026 and upcoming Phase III readouts
Japan ODD Granted Based on StrateGIST 1 Phase I/Ib Trial Data
Japan's Ministry of Health Labour and Welfare granted the ODD supported by data from the ongoing Phase I/Ib StrateGIST 1 trial in advanced GIST, which the announcement states showed promising anti-tumour activity and a promising tolerability profile. Japan was specifically highlighted in the announcement as having one of the highest age-adjusted annual incidences of GIST globally, at approximately 4 per 100,000 people. An additional Phase II trial, StrateGIST J, is already under way in Japan, evaluating patients whose disease has progressed or who are intolerant to available treatment options, underscoring GSK's commitment to this geography.
Velzatinib Targets a Significant Unmet Need Across KIT Mutations in GIST
Velzatinib is designed as a highly selective KIT inhibitor targeting all clinically relevant primary and key secondary KIT mutations in GIST, a rare cancer most commonly arising in the stomach and small intestine. Globally, approximately 80,000 to 120,000 patients are diagnosed with GIST annually, with around 80% of cases driven by KIT gene mutations. The announcement notes that approximately 90% of patients treated in first-line develop secondary KIT resistance mutations, leading to relapse with limited therapeutic options. Critically, no currently approved tyrosine kinase inhibitors inhibit the full spectrum of clinically relevant primary and secondary KIT mutations, representing the unmet medical need velzatinib is designed to address.
Phase III Enrolment Ahead of Schedule with Second-Line Data Expected in 2027
GSK states it is accelerating velzatinib's development, with Phase III studies under way in both first- and second-line advanced or metastatic GIST. Enrolment in the second-line clinical trial is tracking ahead of schedule, which the announcement attributes to strong interest from the GIST community. Data from the second-line Phase III trial are expected in the second half of 2027. Seven abstracts covering velzatinib will be presented at the Connective Tissue Oncology Society Annual Meeting 2026 in Seoul, South Korea, including clinical analyses by KIT mutation and translational biomarker work, providing near-term catalysts for investors monitoring the programme's progress.




Please wait processing your request...